Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital
Indian Journal of Ophthalmology · 2024
DOI: 10.4103/ijo.ijo_562_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2024. Verfasst von Lorenzo Fabozzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Retina, Western Eye Hospital, Imperial College Healthcare NHS Trust, 153-173 Marylebone Rd, London, NW1 5QH, UK. Hauptthemen laut MEDLINE: Intravitreal Injections, Tomography, Optical Coherence, Visual Acuity, Wet Macular Degeneration. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To report real-world clinical evidence of brolucizumab in treating neovascular age-related macular degeneration (nAMD).
Methods
This study included 37 eyes with nAMD treated with intravitreal injections of brolucizumab. The main outcomes were best corrected visual acuity (BCVA) changes, central retinal thickness (CRT), and serious ocular adverse events. Intraretinal fluid (IRF) and subretinal fluid (SRF), subretinal hyperreflective material (SHRM), pigment epithelial detachments (PEDs), hyperreflective foci, macular atrophy, and retinal pigment epithelial tears were evaluated.
Results
The mean BCVA of all patients showed a post-treatment value of 0.47 ± 0.33 log of minimum angle of resolution (LogMAR), compared to a baseline measure of 0.50 ± 0.28 LogMAR ( P = 0.372). For treatment-naïve patients, a non-statistically significant improvement in BCVA was observed ( P = 0.116). Both treatment-naive patients and the entire patient cohort exhibited a statistically significant improvement in the mean CRT after injections. Majority of patients exhibited improvements in optical coherence tomography findings, specifically in the resolution of IRF, SRF, SHRM, and PEDs. Four eyes experienced ocular adverse events in the form of intraocular inflammation.
Conclusion
Brolucizumab did not yield a substantial improvement in BCVA, but it exhibited efficacy in reducing CRT in the entire study population and treatment-naive patients with nAMD. Our study identified intraocular inflammation as a significant adverse event with brolucizumab. Thus, precise patient selection, education, and vigilant inflammation monitoring are crucial for patients undergoing this treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Retina, Western Eye Hospital, Imperial College Healthcare NHS Trust, 153-173 Marylebone Rd, London, NW1 5QH, UK.
- Imperial College Ophthalmology Research Group (ICORG), Imperial College, 153-173 Marylebone Rd, London, NW1 5QH, UK.
- Department of Medical Retina, Moorfields Eye Hospital NHS Foundation Trust, 162 City Rd, London, EC1V 2PD, UK.
- Ramon Castroviejo Institute of Ophthalmic Research Clinic, Complutense University of Madrid, Pl. de Ramón y Cajal, Madrid, Spain.
Zitieren
APA
Fabozzi, L., Younis, S., Sen, S., López-Cuenca, I., & Palmieri, F. (2024). Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_562_24
Vancouver
Fabozzi L, Younis S, Sen S, López-Cuenca I, Palmieri F. Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital. Indian Journal of Ophthalmology. 2024. doi:10.4103/ijo.ijo_562_24
BibTeX
@article{Fabozzi2024,
author = {Fabozzi, Lorenzo and Younis, Saad and Sen, Sagnik and López-Cuenca, Inés and Palmieri, Filomena},
title = {Brolucizumab in patients with neovascular age-related macular degeneration: Real-life outcomes from a tertiary care eye hospital},
journal = {Indian Journal of Ophthalmology},
year = {2024},
doi = {10.4103/ijo.ijo_562_24}
}
EUVIMED